January 24, 2011Annals of Medicine
Old and new anticoagulant drugs: A minireview
Key result
New oral anticoagulants like rivaroxaban and dabigatran are at least as safe and effective as heparins for VTE prophylaxis in high-risk orthopedic surgery, without needing laboratory monitoring.
Population
Patients requiring prophylaxis and treatment of arterial and venous thromboembolism, including those…
Comparison
New oral anticoagulants, including factor Xa… vs Traditional anticoagulants (heparin and warfarin).
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports NOAC consideration for orthopedic VTE prophylaxis; leaves open cost-effectiveness and reversal needs before practice change.
Structured PICO
P
Population
Patients requiring prophylaxis and treatment of arterial and venous thromboembolism, including those undergoing high-risk orthopedic surgery, patients with atrial fibrillation, and patients with ischemic heart disease.
I
Intervention
New oral anticoagulants, including factor Xa inhibitors (e.g., rivaroxaban) and direct thrombin inhibitors (e.g., dabigatran etexilate).
C
Comparator
Traditional anticoagulants (heparin and warfarin).
New oral anticoagulants provide a convenient alternative to traditional agents by eliminating the need for routine laboratory monitoring, though their use is currently limited by high costs and the absence of specific reversal agents.
Limitations
- Lack of specific antidotes for anticoagulation reversal
- High cost
- Available clinical data warrant confirmation and expansion
Cite This Study
Mannucci et al. (2011) conducted a review in Arterial and venous thromboembolism. New anticoagulants (factor Xa and thrombin inhibitors) vs. Traditional anticoagulants (heparin and warfarin) was evaluated. New oral anticoagulants like rivaroxaban and dabigatran are at least as safe and effective as heparins for VTE prophylaxis in high-risk orthopedic surgery, without needing laboratory monitoring.